News

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data
Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...
American Association of Individual Investors4d
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Down 14.69%
Zenas BioPharma, Inc.’s ZBIO share price has dipped by 14.69%, which has investors questioning if this is right time to buy.
American Association of Individual Investors2d
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Up 11.36%
Zenas BioPharma, Inc.’s ZBIO share price has surged by 11.36%, which has investors questioning if this is right time to sell.